Pfizer (PFE) Equity Average (2009 - 2026)

Pfizer has disclosed Equity Average across 18 years of filings, most recently posting $88.3 billion for Q1 2026.

• In Q1 2026, Equity Average fell 1.43% year-over-year to $88.3 billion; the TTM figure through Mar 2026 stood at $88.3 billion (down 1.43% YoY), while the FY2025 annual figure was $87.5 billion, down 3.36% from the prior year.
• Equity Average slipped to $88.3 billion in Q1 2026, from $89.8 billion in the prior quarter.
• Over the last five years, Equity Average for PFE reached as high as $100.3 billion in Q3 2023 and fell as low as $80.1 billion in Q2 2022.
• The 5-year median for Equity Average is $90.3 billion (2024), against an average of $91.2 billion.
• Annual changes were most pronounced in 2022 — Equity Average surged 69.67% — and 2024, when it declined 9.97%.
• A 5-year view of Equity Average shows it stood at $94.4 billion in 2022, then retreated by 1.23% to $93.2 billion in 2023, then declined by 2.92% to $90.5 billion in 2024, then decreased by 0.82% to $89.8 billion in 2025, then fell by 1.67% to $88.3 billion in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $88.3 billion, $89.8 billion, and $91.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.